Top executives from AbbVie took the stage at the 44 th annual JP Morgan Healthcare Conference in San Francisco on Wednesday ...

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen ...

Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, ...

According to Van de Winkel, Genmab is set to enter 2026 with an improved balanced across its earnings, mixing royalties and ...

Michael O'Rourke, CEO of Re-Vana Therapeutics, touches on Re-Vana's transition from an academic spinout to a fully ...

Hayley Burgess SVP, Inovalon, talks about how pharmacies preserve efficiency while strengthening patient care by using ...

Eli Lilly came to the 44 th annual JP Morgan Healthcare Conference bolstered by a strong year. 1 While the looming patent cliff still impacts that company’s upcoming strategy, Lilly found itself in a ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

Bayer's transformation focuses on a revitalized portfolio, strong pipeline, and strategic operational changes for sustained ...

By the end of 2026, the outlines of the next-generation pharmaceutical company will already be taking shape. Organizations that reimagine discovery, reinvent operations, and redesign patient ...

Regeneron's strategy focuses on a broad pipeline across six therapeutic areas, with significant near-term data readouts ...

A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...